Humanized CYP2D6 Mouse

Targeted Replacement

Humanized CYP2D6 Targeted Replacement Mouse Model
Order This Model
CALL: 888.822.6642 + 45 70 23 04 05 (EUROPE)
EZcohort™ Models
The easiest way to acquire and breed cryopreserved GEMs
LEARN MORE

  • Model #
  • Genotype
  • Nomenclature
  • 11584-F
    hu/hu
    C57BL/6-Is(15CYP2D6;Del15Cyp2d22-Cyp2d26)3Arte
  • 11584-M
    hu/hu
    C57BL/6-Is(15CYP2D6;Del15Cyp2d22-Cyp2d26)3Arte

  • This targeted mutation strain carries a replacement of the nine functional mouse Cyp2d genes (Cyp2d22, Cyp2d11, Cyp2d10, Cyp2d9, Cyp2d12, Cyp2d34, Cyp2d13, Cyp2d40, Cyp2d26) with approximately 13 kb of genomic human DNA comprising CYP2D6.
  • CYP2D6 catalyzes the metabolism of more than 20% of drugs in clinical use and is highly polymorphic in humans.
  • May be used as a bioreactor to generate human-specific metabolites, to determine the relevance of CYP2D6 in drug metabolism or for CYP2D6 inhibition studies.
  • May be used with 9178, which is knocked out for the mouse Cyp2d cluster, to predict the differences in response of human poor and extensive CYP2D6 metabolisers.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:

C57BL/6 Background

Origin:

The Humanized CYP2D6 Mouse was developed by Taconic in collaboration with CXR Biosciences. It was created by first replacing mouse exon 1 to 4 of Cyp2d26 with a hygromycin cassette containing both loxP and frt sites and subsequently replacing mouse exons 4 and 5 of Cyp2d22 with a genomic human CYP2D6 expression cassette containing additional loxP and frt sites through gene targeting in C57BL/6NTac-derived ES cells. The targeted ES cells were injected into BALB/cJBomTac blastocysts and the resultant chimeras were backcrossed to a Cre deleter strain on C57BL/6J to delete the mouse Cyp2d cluster, while retaining the human CYP2D6 expression cassette. The colony is maintained by mating homozygotes.


Color:

Black

Species:

Mouse

Initial Publication:

Scheer et al. (2012) Modeling Human Cytochrome P450 2D6 Metabolism and Drug-Drug Interaction by a Novel Panel of Knockout and Humanized Mouse Lines. Mol Pharmacol. (2012) Jan;81(1):63-72.



Conditions of Use for EZcohort™ Models
EZcohort™ models are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic Biosciences, Inc. (Taconic) sells EZcohort™ models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased EZcohort™ models in consideration of purchasers' acknowledgement of and agreement to Taconic's Terms and Conditions for the Sale of Products and the following conditions of use:

  • Title to EZcohort™ models and biological materials derived from them remains with Taconic.
  • EZcohort™ models will be used for research purposes only.
  • EZcohort™ models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Breeders from deliverables can be used for propagation of EZcohort™ models or to cross to other strains.
  • Continuation of breeding and crossbreeding of EZcohort™ models outside Taconicis permitted for a term of three years post-purchase of the EZcohort™ models and is subject to annual confirmation of these EZcohort™ Conditions of Use.

Continuation of breeding and crossbreeding after the three year term will require renewal of the EZcohort™ Conditions of Use and payment of a fee.